FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892640821> ?p ?o ?g. }

• W2892640821 endingPage "2051" @default.
• W2892640821 startingPage "2040" @default.
• W2892640821 abstract "Standard first-line therapy for metastatic, squamous non-small-cell lung cancer (NSCLC) is platinum-based chemotherapy or pembrolizumab (for patients with programmed death ligand 1 [PD-L1] expression on ≥50% of tumor cells). More recently, pembrolizumab plus chemotherapy was shown to significantly prolong overall survival among patients with nonsquamous NSCLC.In this double-blind, phase 3 trial, we randomly assigned, in a 1:1 ratio, 559 patients with untreated metastatic, squamous NSCLC to receive 200 mg of pembrolizumab or saline placebo for up to 35 cycles; all the patients also received carboplatin and either paclitaxel or nanoparticle albumin-bound [nab]-paclitaxel for the first 4 cycles. Primary end points were overall survival and progression-free survival.After a median follow-up of 7.8 months, the median overall survival was 15.9 months (95% confidence interval [CI], 13.2 to not reached) in the pembrolizumab-combination group and 11.3 months (95% CI, 9.5 to 14.8) in the placebo-combination group (hazard ratio for death, 0.64; 95% CI, 0.49 to 0.85; P<0.001). The overall survival benefit was consistent regardless of the level of PD-L1 expression. The median progression-free survival was 6.4 months (95% CI, 6.2 to 8.3) in the pembrolizumab-combination group and 4.8 months (95% CI, 4.3 to 5.7) in the placebo-combination group (hazard ratio for disease progression or death, 0.56; 95% CI, 0.45 to 0.70; P<0.001). Adverse events of grade 3 or higher occurred in 69.8% of the patients in the pembrolizumab-combination group and in 68.2% of the patients in the placebo-combination group. Discontinuation of treatment because of adverse events was more frequent in the pembrolizumab-combination group than in the placebo-combination group (13.3% vs. 6.4%).In patients with previously untreated metastatic, squamous NSCLC, the addition of pembrolizumab to chemotherapy with carboplatin plus paclitaxel or nab-paclitaxel resulted in significantly longer overall survival and progression-free survival than chemotherapy alone. (Funded by Merck Sharp & Dohme; KEYNOTE-407 ClinicalTrials.gov number, NCT02775435 .)." @default.
• W2892640821 created "2018-10-05" @default.
• W2892640821 creator A5001428569 @default.
• W2892640821 creator A5005962138 @default.
• W2892640821 creator A5008061093 @default.
• W2892640821 creator A5008382382 @default.
• W2892640821 creator A5010421355 @default.
• W2892640821 creator A5018757509 @default.
• W2892640821 creator A5019233587 @default.
• W2892640821 creator A5021014213 @default.
• W2892640821 creator A5023317984 @default.
• W2892640821 creator A5034912444 @default.
• W2892640821 creator A5052765751 @default.
• W2892640821 creator A5055246540 @default.
• W2892640821 creator A5057704753 @default.
• W2892640821 creator A5061690935 @default.
• W2892640821 creator A5068491805 @default.
• W2892640821 creator A5070782948 @default.
• W2892640821 creator A5073085972 @default.
• W2892640821 creator A5075417603 @default.
• W2892640821 creator A5075510355 @default.
• W2892640821 creator A5080846994 @default.
• W2892640821 creator A5081356537 @default.
• W2892640821 creator A5085720544 @default.
• W2892640821 creator A5091073688 @default.
• W2892640821 date "2018-11-22" @default.
• W2892640821 modified "2023-10-18" @default.
• W2892640821 title "Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer" @default.
• W2892640821 cites W1982488143 @default.
• W2892640821 cites W2019607817 @default.
• W2892640821 cites W2030455138 @default.
• W2892640821 cites W2068762252 @default.
• W2892640821 cites W2076668534 @default.
• W2892640821 cites W2156353875 @default.
• W2892640821 cites W2167599107 @default.
• W2892640821 cites W2198093519 @default.
• W2892640821 cites W2472596403 @default.
• W2892640821 cites W2511043440 @default.
• W2892640821 cites W2527905628 @default.
• W2892640821 cites W2529904548 @default.
• W2892640821 cites W2567564314 @default.
• W2892640821 cites W2599537025 @default.
• W2892640821 cites W2635951006 @default.
• W2892640821 cites W2753529762 @default.
• W2892640821 cites W2767664311 @default.
• W2892640821 cites W2770609569 @default.
• W2892640821 cites W2796582438 @default.
• W2892640821 cites W2797675588 @default.
• W2892640821 cites W2806145489 @default.
• W2892640821 cites W2806388842 @default.
• W2892640821 cites W2888059202 @default.
• W2892640821 cites W2892009523 @default.
• W2892640821 doi "https://doi.org/10.1056/nejmoa1810865" @default.
• W2892640821 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30280635" @default.
• W2892640821 hasPublicationYear "2018" @default.
• W2892640821 type Work @default.
• W2892640821 sameAs 2892640821 @default.
• W2892640821 citedByCount "2376" @default.
• W2892640821 countsByYear W28926408212017 @default.
• W2892640821 countsByYear W28926408212018 @default.
• W2892640821 countsByYear W28926408212019 @default.
• W2892640821 countsByYear W28926408212020 @default.
• W2892640821 countsByYear W28926408212021 @default.
• W2892640821 countsByYear W28926408212022 @default.
• W2892640821 countsByYear W28926408212023 @default.
• W2892640821 crossrefType "journal-article" @default.
• W2892640821 hasAuthorship W2892640821A5001428569 @default.
• W2892640821 hasAuthorship W2892640821A5005962138 @default.
• W2892640821 hasAuthorship W2892640821A5008061093 @default.
• W2892640821 hasAuthorship W2892640821A5008382382 @default.
• W2892640821 hasAuthorship W2892640821A5010421355 @default.
• W2892640821 hasAuthorship W2892640821A5018757509 @default.
• W2892640821 hasAuthorship W2892640821A5019233587 @default.
• W2892640821 hasAuthorship W2892640821A5021014213 @default.
• W2892640821 hasAuthorship W2892640821A5023317984 @default.
• W2892640821 hasAuthorship W2892640821A5034912444 @default.
• W2892640821 hasAuthorship W2892640821A5052765751 @default.
• W2892640821 hasAuthorship W2892640821A5055246540 @default.
• W2892640821 hasAuthorship W2892640821A5057704753 @default.
• W2892640821 hasAuthorship W2892640821A5061690935 @default.
• W2892640821 hasAuthorship W2892640821A5068491805 @default.
• W2892640821 hasAuthorship W2892640821A5070782948 @default.
• W2892640821 hasAuthorship W2892640821A5073085972 @default.
• W2892640821 hasAuthorship W2892640821A5075417603 @default.
• W2892640821 hasAuthorship W2892640821A5075510355 @default.
• W2892640821 hasAuthorship W2892640821A5080846994 @default.
• W2892640821 hasAuthorship W2892640821A5081356537 @default.
• W2892640821 hasAuthorship W2892640821A5085720544 @default.
• W2892640821 hasAuthorship W2892640821A5091073688 @default.
• W2892640821 hasBestOaLocation W28926408211 @default.
• W2892640821 hasConcept C121608353 @default.
• W2892640821 hasConcept C126322002 @default.
• W2892640821 hasConcept C141071460 @default.
• W2892640821 hasConcept C142724271 @default.
• W2892640821 hasConcept C143998085 @default.
• W2892640821 hasConcept C204787440 @default.
• W2892640821 hasConcept C207103383 @default.
• W2892640821 hasConcept C27081682 @default.

• next